A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis

Mira Ghaly, Corin Seelemann, Arezu Jahani-Asl

Research output: Contribution to journalComment/debatepeer-review

4 Scopus citations

Abstract

Chordoma is a rare primary bone cancer with limited treatment options. Surgical resection followed by radiotherapy has proven effective; however, when, in 30–40% of patients, tumours recur and metastasize, a high level of resistance to chemotherapies leaves these patients with a dearth of treatment options. Recent work published in the Journal of Pathology by Scheipl et al describing a focused compound drug screen highlights the significance of epidermal growth factor receptor (EGFR) signalling in chordoma, and shows potential for EGFR inhibitors as a way forward for developing an effective treatment for chordoma. Importantly, combining EGFR inhibitors with a MET inhibitor induces a synergistic effect on growth inhibition of resistant chordoma cells, highlighting the significance of combined EGFR and MET inhibitors as a potential avenue to defeat chemoresistance in chordoma patients.

Original languageEnglish (US)
Pages (from-to)381-383
Number of pages3
JournalJournal of Pathology
Volume240
Issue number4
DOIs
StatePublished - Dec 1 2016

Keywords

  • EGFR inhibitors
  • MET inhibitors
  • chordoma
  • compound drug screen
  • crizotinib
  • met
  • sapitinib

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint Dive into the research topics of 'A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis'. Together they form a unique fingerprint.

Cite this